Ironwood Pharmaceuticals (IRWD)
Develops gastrointestinal therapies around LINZESS and apraglutide.
Something off on this page? Send us feedback.
Builds its business around LINZESS, a prescription treatment for IBS-C and CIC, and a partner-led commercialization model. Develops apraglutide for adults with short bowel syndrome and intestinal failure.
Commercializes LINZESS, its in-house-discovered linaclotide product for adults with IBS-C and CIC. AbbVie leads commercialization in the United States, while AstraZeneca covers China and Astellas covers Japan.
Develops apraglutide, a long-acting synthetic GLP-2 analogue, for adults with short bowel syndrome and intestinal failure. Access to the program is limited to clinical trials as the STARS program continues.
Operates as a single human-therapeutics segment with one mature commercial franchise and a rare-disease pipeline expansion. The model depends on the LINZESS collaboration's shared sales and cost structure and on confirmatory clinical and regulatory progress for apraglutide.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 26, 2026 | Jefferies | Target | Target: — | Target: $3.70 |
| Jan 5, 2026 | Craig-Hallum | Target | Target: $3.80 | Target: $5.70 |
| Jan 5, 2026 | Citizens | Upgrade | ||
| Jan 4, 2026 | Wells Fargo | Target | Target: $7 | Target: $5 |
| Nov 26, 2025 | Craig-Hallum | Target | Target: — | Target: $3.80 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $79.1M · Total debt $396.9M · Total assets $285.1M · Shareholders' equity −$161.8M
- Revenue
- $113.0M
- Operating income
- $79.3M
- Net income
- $51.3M
No dividends on record.
| Institutions | ≈ 98.82% | 163.30M shares | |
|---|---|---|---|
| 220 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 16.48% | 27.24M shares | |
| 17 holders · as of Sep 17, 2026 | |||
| Adds to | 115.30% | ||
165.24M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.30%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.77% | 17.79M | as of Jun 30, 2026 |
Brown Capital Management, LLCInstitution | 9.84% | 16.26M | filed Feb 14, 2022 |
Armistice Capital, LLCInstitution | 8.43% | 13.93M | as of Jun 30, 2026 |
Pacer US Small Cap Cash Cows ETFInsider | 7.09% | 11.71M | filed May 2, 2025 |
Alexander J. Denner1,2Insiderdirector | 5.76% | 9.44M | filed Sep 17, 2026 |
- Alexander J. Denner's transaction reports restate only vehicles that traded; the 2026 ownership statement (9.44M) plus the 71.2K net shares acquired since is used instead.
- Alexander J. Denner reports a block also reported by Sarissa Capital Management LP; it is counted once, under Sarissa Capital Management LP.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 7, 2026 | Ronald Silver | officer: PFO & PAO | −127,890 | $4.52 |
| Jun 16, 2026 | Julie McHugh | director | −21,571 | $3.73 |
| Mar 17, 2026 | Alexander J. Denner | director | −6,730,800 | $3.05 |
| Feb 24, 2026 | Ronald Silver | officer: Principal Accounting Officer | −12,621 | $3.66 |
| Feb 23, 2026 | Ronald Silver | officer: Principal Accounting Officer | −11,552 | $3.81 |
- Bausch Health
Branded CIC and IBS-C therapy with TRULANCE
- Ardelyx
IBS-C therapy with IBSRELA and a CIC expansion program
- Takeda (ADR)
Marketed GLP-2 therapy for SBS patients on parenteral support
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals | $4.52 | −0.22% | $725.9M | 5.7 | 3.6 | 1.9 | +32.6% |
| Bausch Health | $5.80 | −0.09% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| Ardelyx | $3.63 | −0.00% | $864.6M | — | — | 1.9 | +23.8% |
| Takeda (ADR) | $18.89 | −0.34% | $60.11B | 52.5 | 59.9 | 2.0 | +4.2% |
| Median | 52.5 | 30.6 | 1.9 | +11.2% |